



Supplementary figure 1




Supplementary figure 2

A



B



Supplementary table 1. Characteristics of patients with chronic myelogenous leukemia

Patient No	Age (yr)/ Sex	Date of Diagnosis	Prior Therapy	Date imatinib therapy began	Date resistance recorded	Time to Progression (months)	Stage of resistance	WBC count (10 ⁹ /L)	Bcr-Abl positive
1	73/M	7/2004	interferon, hydroxyurea	1/2007	11/2007	10	CP	5.90	Yes
2	48/M	4/2004	interferon, hydroxyurea	6/2005	6/2007	24	AP	5.77	Yes
3	53/M	5/2005	hydroxyurea	7/2005	12/2007	29	CP	6.20	Yes
4	24/F	11/2003	interferon, hydroxyurea	11/2004	12/2007	37	CP	5.50	Yes
5	36/M	10/2005	no treatment	10/2005	10/2007	24	CP	5.00	Yes
6	52/F	5/2005	hydroxyurea	1/2008			BP	15.84	Yes
7	17/M	6/2006	hydroxyurea	12/2007			BP	1.41	Yes

CP: chronic phase; AP: Accelerated phase; BP: blast crisis phase; WBC: white blood cell counted when blood samples were drawn;